PMID- 35039078
OWN - NLM
STAT- MEDLINE
DCOM- 20220121
LR  - 20220121
IS  - 2050-6511 (Electronic)
IS  - 2050-6511 (Linking)
VI  - 23
IP  - 1
DP  - 2022 Jan 17
TI  - Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump 
      inhibitor and histamine-2 receptor antagonist short-term users: a nationwide 
      retrospective cohort study.
PG  - 9
LID - 10.1186/s40360-022-00549-7 [doi]
LID - 9
AB  - BACKGROUND: This study aimed to evaluate incidence risk and adverse clinical 
      outcomes in COVID-19 disease among short-term users of acid-suppressants in South 
      Korea. METHODS: This retrospective cohort study, conducted using a nationwide 
      claims database for South Korea, used data from patients with COVID-19 tested 
      between January 1 and May 15, 2020. Patients aged over 18 years and prescribed 
      proton pump inhibitors (PPI) or histamine-2 receptor antagonist (H(2)RA) for more 
      than 7 days were identified. Primary outcome was COVID-19 while secondary 
      outcomes were all-cause mortality, hospitalization with respiratory disease, or 
      intensive respiratory intervention. Large-scale propensity scores were used to 
      match patients, while the Cox proportional hazard model was utilized to evaluate 
      any association between exposure and outcome(s). The risk estimates were 
      calibrated by using 123 negative control outcomes. RESULTS: We identified 26,166 
      PPI users and 62,117 H(2)RA users. After propensity score matching, compared to 
      H(2)RA use, PPI use was not significantly associated with lower risk of COVID-19 
      (calibrated hazard ratio [HR], 0.81 [95% confidence interval (CI), 0.30-2.19]); 
      moreover, PPI use was not associated with adverse clinical outcomes in COVID-19, 
      namely, hospitalization with respiratory disease (calibrated HR, 0.88 [95% CI, 
      0.72-1.08]), intensive respiratory interventions (calibrated HR, 0.92 [95% CI, 
      0.46-1.82]), except for all-cause mortality (calibrated HR, 0.54 [95% CI, 
      0.31-0.95]). CONCLUSIONS: In this study, we found that the PPI user was not 
      associated with risk of COVID-19 compared to H(2)RA users. There was no 
      significant relationship between severe clinical outcomes of COVID-19 and 
      exposure to PPI compared with H(2)RA, except for all-cause mortality.
CI  - (c) 2022. The Author(s).
FAU - Park, Jimyung
AU  - Park J
AD  - Department of Biomedical Sciences, Ajou University Graduate School of Medicine, 
      164, World cup-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16499, Republic of Korea.
FAU - You, Seng Chan
AU  - You SC
AD  - Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Cho, Jaehyeong
AU  - Cho J
AD  - Department of Biomedical Sciences, Ajou University Graduate School of Medicine, 
      164, World cup-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16499, Republic of Korea.
FAU - Park, Chan Hyuk
AU  - Park CH
AD  - Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang 
      University College of Medicine, Guri, Republic of Korea.
FAU - Shin, Woon Geon
AU  - Shin WG
AD  - Division of Gastroenterology, Department of Internal Medicine, Kangdong Sacred 
      Heart Hospital, Hallym University College of Medicine, 150, Seongan-ro, Seoul, 
      Gangdong-gu, 05355, South Korea.
FAU - Park, Rae Woong
AU  - Park RW
AD  - Department of Biomedical Sciences, Ajou University Graduate School of Medicine, 
      164, World cup-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16499, Republic of Korea. 
      veritas@ajou.ac.kr.
AD  - Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, 
      Gyeonggi-do, Republic of Korea. veritas@ajou.ac.kr.
FAU - In Seo, Seung
AU  - In Seo S
AD  - Division of Gastroenterology, Department of Internal Medicine, Kangdong Sacred 
      Heart Hospital, Hallym University College of Medicine, 150, Seongan-ro, Seoul, 
      Gangdong-gu, 05355, South Korea. doctorssi@kdh.or.kr.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220117
PL  - England
TA  - BMC Pharmacol Toxicol
JT  - BMC pharmacology & toxicology
JID - 101590449
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - COVID-19/complications/*epidemiology/therapy
MH  - Female
MH  - Histamine H2 Antagonists/*therapeutic use
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Republic of Korea/epidemiology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *SARS-CoV-2
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC8762632
OTO - NOTNLM
OT  - Acid suppressants
OT  - Epidemiology
OT  - Pharmacovigilance
OT  - Retrospective studies
COIS- The authors declare that they have no competing interests.
EDAT- 2022/01/19 06:00
MHDA- 2022/01/22 06:00
PMCR- 2022/01/17
CRDT- 2022/01/18 05:37
PHST- 2021/09/07 00:00 [received]
PHST- 2022/01/11 00:00 [accepted]
PHST- 2022/01/18 05:37 [entrez]
PHST- 2022/01/19 06:00 [pubmed]
PHST- 2022/01/22 06:00 [medline]
PHST- 2022/01/17 00:00 [pmc-release]
AID - 10.1186/s40360-022-00549-7 [pii]
AID - 549 [pii]
AID - 10.1186/s40360-022-00549-7 [doi]
PST - epublish
SO  - BMC Pharmacol Toxicol. 2022 Jan 17;23(1):9. doi: 10.1186/s40360-022-00549-7.